000303014 001__ 303014
000303014 005__ 20250727021620.0
000303014 0247_ $$2doi$$a10.1016/j.lungcan.2025.108640
000303014 0247_ $$2pmid$$apmid:40651130
000303014 0247_ $$2ISSN$$a0169-5002
000303014 0247_ $$2ISSN$$a1872-8332
000303014 0247_ $$2altmetric$$aaltmetric:178910187
000303014 037__ $$aDKFZ-2025-01461
000303014 041__ $$aEnglish
000303014 082__ $$a610
000303014 1001_ $$aLanger, Susan$$b0
000303014 245__ $$aTherapeutic modalities for superior sulcus tumor (Pancoast) tumor - A systematic review.
000303014 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2025
000303014 3367_ $$2DRIVER$$aarticle
000303014 3367_ $$2DataCite$$aOutput Types/Journal article
000303014 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1753095536_5172$$xReview Article
000303014 3367_ $$2BibTeX$$aARTICLE
000303014 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303014 3367_ $$00$$2EndNote$$aJournal Article
000303014 500__ $$a#LA:C020#
000303014 520__ $$aSuperior sulcus tumors (SST) are usually treated with multimodal therapy, mainly trimodal therapy encompassing radiochemotherapy (CRT) followed by surgery. However, high-level evidence from randomized trials remains limited. We conducted a systematic review to assess the evidence of treatment strategies considering adverse events and oncologic outcomes.We systematically searched MEDLINE, CINAHL, EMBASE, Web of Science, CENTRAL, grey literature databases, and clinical trial registries. We included prospective and retrospective studies published between 1990 and 2024 with mono-, bi- or trimodal treatment reporting outcomes such as overall survival (OS), progression-free survival (PFS), resection rates, postoperative mortality/morbidity, and adverse events. Studies required histologically confirmed SST and a minimum of 30 patients.Thirty-five studies were included (28 retrospective, 7 prospective), with follow-up ranging from 10 to 107 months. Most studies originated from Europe (n = 16) and North America (n = 14). Sample sizes ranged from 30 to 2910 patients, predominantly male and aged in the late 50s to early 60s. Induction CRT protocols varied widely. R0 resection rates were reported in 33 studies, and trimodal therapy outcomes in 12. Hematotoxicity and esophagitis were the most common adverse events. Five-year OS rates varied between 11.8 % and 77 %, with trimodal therapy associated with better survival and distant metastasis as the dominant recurrence pattern. There were no studies addressing immunotherapy.While trimodal therapy remains the guideline-endorsed standard for SST, comparative evidence remains sparse. The role of immunotherapy in induction regimens warrants further investigation.
000303014 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000303014 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303014 650_7 $$2Other$$aLung cancer
000303014 650_7 $$2Other$$aNSCLC
000303014 650_7 $$2Other$$aRadiochemotherapy
000303014 650_7 $$2Other$$aSulcus superior tumor
000303014 650_7 $$2Other$$aSystematic review
000303014 7001_ $$aMedenwald, Daniel$$b1
000303014 7001_ $$aVordermark, Dirk$$b2
000303014 7001_ $$aSchuette, Wolfgang$$b3
000303014 7001_ $$aDeppermann, Karl-Matthias$$b4
000303014 7001_ $$aNothacker, Monika$$b5
000303014 7001_ $$aEggeling, Stephan$$b6
000303014 7001_ $$0P:(DE-He78)4079aa080622f0e0073d820b2f32f423$$aEfremov, Ljupcho$$b7$$eLast author$$udkfz
000303014 773__ $$0PERI:(DE-600)2025812-4$$a10.1016/j.lungcan.2025.108640$$gVol. 206, p. 108640 -$$p108640$$tLung cancer$$v206$$x0169-5002$$y2025
000303014 909CO $$ooai:inrepo02.dkfz.de:303014$$pVDB
000303014 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4079aa080622f0e0073d820b2f32f423$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000303014 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000303014 9141_ $$y2025
000303014 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
000303014 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000303014 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000303014 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000303014 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000303014 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
000303014 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000303014 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000303014 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLUNG CANCER : 2022$$d2024-12-11
000303014 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-11
000303014 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-11
000303014 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bLUNG CANCER : 2022$$d2024-12-11
000303014 9202_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000303014 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000303014 980__ $$ajournal
000303014 980__ $$aVDB
000303014 980__ $$aI:(DE-He78)C020-20160331
000303014 980__ $$aUNRESTRICTED